Skip to main content
. 2014 Nov 7;15(11):20500–20517. doi: 10.3390/ijms151120500

Figure 6.

Figure 6

Dose-dependency of sorafenib effects on cell viability in combination with the Bcl-2 inhibitor ABT-737 as measured by total ATP levels, shown exemplarily in T24 cells. Cells were treated with both compounds over (a) 24 and (b) 72 h.